VEGF

hot
Biotech

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific

Pfizer has bagged ex-China rights, establishing itself as a challenger to BioNTech, Merck and Summit in a scorching-hot area of immuno-oncology.
Nick Paul Taylor May 20, 2025 4:47am
iris eye eyeball eye art

Kodiak resurrects eye drug after ph. 3 data renew approval plans

Nov 6, 2023 8:40am
Moderna manufacturing site

Clean up on IL-2: Moderna mops up autoimmune asset

Aug 3, 2022 10:59am
Yale University campus - red building and a quadrangle with trees

Could a glaucoma drug also fight obesity?

Aug 10, 2018 10:25am